

# Laura Nuño-Nuño

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1029984/publications.pdf>

Version: 2024-02-01

37  
papers

983  
citations

623734

14  
h-index

454955

30  
g-index

40  
all docs

40  
docs citations

40  
times ranked

1258  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients. <i>Journal of Clinical Rheumatology</i> , 2022, 28, e195-e202.	0.9	5
2	Study of Plasma Anti-CD26 Autoantibody Levels in a Cohort of Treatment-Naïve Early Arthritis Patients. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2022, 70, 12.	2.3	2
3	Achievement rate and predictive factors of the recommended therapeutical target in patients with axial spondyloarthritis who remain on biological therapy: a prospective cohort study in Spain. <i>BMJ Open</i> , 2022, 12, e057850.	1.9	8
4	HLA association with the susceptibility to anti-synthetase syndrome. <i>Joint Bone Spine</i> , 2021, 88, 105115.	1.6	8
5	Myo-Spain: Registro de pacientes con miopatía inflamatoria idiopática de España. <i>Metodología Reumatológica Clínica</i> , 2021, , .	0.5	0
6	<i>HLA-B*08</i> Identified as the Most Prominently Associated Major Histocompatibility Complex Locus for Anti-Carbamylated Protein Antibody-Positive/Anti-Cyclic Citrullinated Peptide-Negative Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2021, 73, 963-969.	5.6	12
7	Myo-Spain: Spanish Registry of patients with idiopathic inflammatory myopathy. <i>Methodology. Reumatológica Clínica (English Edition)</i> , 2021, , .	0.3	0
8	The Macrophage Reprogramming Ability of Antifolates Reveals Soluble CD14 as a Potential Biomarker for Methotrexate Response in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , 2021, 12, 776879.	4.8	7
9	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. <i>Scientific Reports</i> , 2021, 11, 22574.	3.3	4
10	Improved classification of rheumatoid arthritis with a score including anti-acetylated ornithine antibodies. <i>Scientific Reports</i> , 2020, 10, 19263.	3.3	10
11	Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2020, 22, 284.	3.5	28
12	Circulating CD19+CD24hiCD38hi regulatory B cells as biomarkers of response to methotrexate in early rheumatoid arthritis. <i>Rheumatology</i> , 2020, 59, 3081-3091.	1.9	7
13	Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1659-1661.	0.9	67
14	A predominant involvement of the triple seropositive patients and others with rheumatoid factor in the association of smoking with rheumatoid arthritis. <i>Scientific Reports</i> , 2020, 10, 3355.	3.3	20
15	Influence of MUC5B gene on antisynthetase syndrome. <i>Scientific Reports</i> , 2020, 10, 1415.	3.3	12
16	Correspondence on: EULAR definition of difficult-to-treat rheumatoid arthritis™. <i>Annals of the Rheumatic Diseases</i> , 2020, , annrheumdis-2020-219500.	0.9	3
17	Lower frequency of anti-citrullinated protein antibodies among early arthritis patients with high body mass index. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 1155-1160.	0.8	1
18	Two populations of circulating PD-1hiCD4 T cells with distinct B cell helping capacity are elevated in early rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 1662-1673.	1.9	48

#	ARTICLE	IF	CITATIONS
19	Overlap myositis, a distinct entity beyond primary inflammatory myositis: A retrospective analysis of a large cohort from the REMICAM registry. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 1393-1401.	1.9	28
20	AB0636â€¦INFLUENCE OF CARDIOVASCULAR RISK FACTORS ON NAILFOLD VIDEOCAPILLAROSCOPY IN THE STUDY OF CONNECTIVE TISSUE DISEASES. , 2019, , .		0
21	FRIO424â€¦DIFFERENCES AND SIMILARITIES ACCORDING TO GENDER IN PATIENTS WITH PSORIATIC ARTHRITIS INITIATING BIOLOGICAL THERAPY. , 2019, , .		0
22	FRIO079â€¦LONG-TERM CLINICAL EFFICACY OF CYCLING VS SWITCHING TO A NON-TNF INHIBITOR IN RA PATIENTS WHO FAILED TO A FIRST TNF INHIBITOR. , 2019, , .		0
23	SAT0063â€¦ASSOCIATION OF SMOKING WITH TRIPLE CONCORDANT SEROPOSITIVITY IN RA PATIENTS, AND WITH RHEUMATOID FACTOR IN THE REMAINING PATIENTS. , 2019, , .		0
24	THU0096â€¦PERSISTENT HIGH DISEASE ACTIVITY IN THE ANTI-CARBAMYLATED PROTEIN ANTIBODY POSITIVE EARLY ARTHRITIS PATIENTS INDEPENDENTLY OF TREATMENT. , 2019, , .		0
25	Influence of Antisynthetase Antibodies Specificities on Antisynthetase Syndrome Clinical Spectrum Time Course. <i>Journal of Clinical Medicine</i> , 2019, 8, 2013.	2.4	118
26	Long-term pulmonary outcomes and mortality in idiopathic inflammatory myopathies associated with interstitial lung disease. <i>Clinical Rheumatology</i> , 2019, 38, 803-815.	2.2	27
27	Specific Association of HLA â€œ DRB 1*03 With Antiâ€œCarbamylated Protein Antibodies in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 331-339.	5.6	13
28	Timing of onset affects arthritis presentation pattern in antisynthetase syndrome. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 44-49.	0.8	30
29	Serum Jo-1 Autoantibody and Isolated Arthritis in the Antisynthetase Syndrome: Review of the Literature and Report of the Experience of AENEAS Collaborative Group. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 71-80.	6.5	60
30	Clinical follow-up predictors of disease pattern change in anti-Jo1 positive anti-synthetase syndrome: Results from a multicenter, international and retrospective study. <i>Autoimmunity Reviews</i> , 2017, 16, 253-257.	5.8	46
31	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.9	209
32	Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients. <i>Scientific Reports</i> , 2017, 7, 12023.	3.3	17
33	Multicenter Registry on Inflammatory Myositis From the Rheumatology Society in Madrid, Spain: Descriptive Analysis. <i>ReumatologÃa ClÃnica (English Edition)</i> , 2017, 13, 331-337.	0.3	6
34	Registro de pacientes con miopatÃa inflamatoria de la Sociedad MadrileÃa de ReumatologÃa: anÃlisis descriptivo. <i>ReumatologÃa ClÃnica</i> , 2017, 13, 331-337.	0.5	14
35	Mortality and prognostic factors in idiopathic inflammatory myositis: a retrospective analysis of a large multicenter cohort of Spain. <i>Rheumatology International</i> , 2017, 37, 1853-1861.	3.0	32
36	Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1144.	1.0	133

#	ARTICLE	IF	CITATIONS
37	Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations: A Cohort Study in Clinical Practice Conditions. <i>Frontiers in Medicine</i> , 2015, 2, 71.	2.6	8